Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Work In Process (2025)

Soleno Therapeutics (SLNO) has disclosed Work In Process for 1 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Work In Process changed N/A to $2.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.7 million, a N/A change, with the full-year FY2025 number at $2.7 million, changed N/A from a year prior.
  • Work In Process was $2.7 million for Q4 2025 at Soleno Therapeutics, up from $2.0 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $2.7 million in Q4 2025 to a low of $950000.0 in Q2 2025.